T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients

To clarify the molecular background underlying the heterogeneity of multiple sclerosis (MS), we characterized the gene expression profile of peripheral blood CD3+ T cells isolated from MS and healthy control (CN) subjects by using a cDNA microarray. Among 1258 cDNAs on the array, 286 genes were expressed differentially between 72 untreated Japanese MS patients and 22 age- and sex-matched CN subjects. When this set was used as a discriminator for hierarchical clustering analysis, it identified four distinct subgroups of MS patients and five gene clusters differentially expressed among the subgroups. One of these gene clusters was overexpressed in MS versus CN, and particularly enhanced in the clinically most active subgroup of MS. After 46 of the MS patients were treated with interferon-beta (IFNbeta-1b) for two years, IFNbeta responders were clustered in two of the four MS subgroups. Furthermore, the IFNbeta responders differed from nonresponders in the kinetics of IFN-responsive genes at 3 and 6 months after starting IFNbeta treatment. These results suggest that T-cell gene expression profiling is valuable to identify distinct subgroups of MS associated with differential disease activity and therapeutic response to IFNbeta.

[1]  Gveric,et al.  Insulin‐like growth factors and binding proteins in multiple sclerosis plaques , 1999, Neuropathology and applied neurobiology.

[2]  H. Weiner,et al.  CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[3]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[4]  R. Reynolds,et al.  Molecular Changes in Normal Appearing White Matter in Multiple Sclerosis are Characteristic of Neuroprotective Mechanisms Against Hypoxic Insult , 2003, Brain pathology.

[5]  J. Menonna,et al.  Platelet‐derived growth factor‐α receptor‐positive oligodendroglia are frequent in multiple sclerosis lesions , 2001 .

[6]  D. Hafler,et al.  Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions , 1995, The Journal of experimental medicine.

[7]  G. Opdenakker,et al.  Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis , 2003, The Lancet Neurology.

[8]  S. Hulshof,et al.  Cellular localization and expression patterns of interleukin‐10, interleukin‐4, and their receptors in multiple sclerosis lesions , 2002, Glia.

[9]  N. Peress,et al.  Glial transforming growth factor (TGF)-β isotypes in multiple sclerosis: differential glial expression of TGF-β1, 2 and 3 isotypes in multiple sclerosis , 1996, Journal of Neuroimmunology.

[10]  P. Aarnisalo,et al.  Regulation of the osteopontin gene by the orphan nuclear receptor NURR1 in osteoblasts. , 2004, Molecular endocrinology.

[11]  R. Hirsch,et al.  Treatment of multiple sclerosis with gamma interferon , 1987, Neurology.

[12]  Pierre Baldi,et al.  A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes , 2001, Bioinform..

[13]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[14]  L. Staudt,et al.  Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. , 2003, Brain : a journal of neurology.

[15]  L. Steinman,et al.  Transcriptional analysis of targets in multiple sclerosis , 2003, Nature Reviews Immunology.

[16]  A. Achiron,et al.  Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus , 2004, Clinical and experimental immunology.

[17]  M. Ramanathan,et al.  Detection of cytochrome P450 and other drug-metabolizing enzyme mRNAs in peripheral blood mononuclear cells using DNA arrays. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[18]  S. Vukusic,et al.  Clinical characteristics of responders to interferon therapy for relapsing MS , 2003, Neurology.

[19]  Hong Zhang,et al.  The FASEB Journal express article 10.1096/fj.02-1131fje. Published online September 4, 2003. Expression and functional characterization of ABCG2 in brain endothelial cells and vessels , 2022 .

[20]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[21]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[22]  R. Takayanagi,et al.  cDNA cloning of a NGFI-B/nur77-related transcription factor from an apoptotic human T cell line. , 1995, Journal of immunology.

[23]  J H Simon,et al.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.

[24]  J. Satoh,et al.  Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis , 2005, Neurobiology of Disease.

[25]  Pingar Yang,et al.  Inhibition of Nur77/Nurr1 leads to inefficient clonal deletion of self- reactive T cells , 1996, The Journal of experimental medicine.

[26]  C. Bisbal,et al.  Cloning and Characterization of a RNase L Inhibitor. , 1995, The Journal of Biological Chemistry.

[27]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[28]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[29]  L. Griffiths,et al.  Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. , 2003, Brain research. Molecular brain research.

[30]  L. Staudt,et al.  Gene expression physiology and pathophysiology of the immune system. , 2001, Trends in immunology.

[31]  Lawrence Steinman,et al.  Multiple sclerosis: a two-stage disease , 2001, Nature Immunology.

[32]  Nir Friedman,et al.  Blood transcriptional signatures of multiple sclerosis: Unique gene expression of disease activity , 2004, Annals of neurology.

[33]  Jorge R. Oksenberg,et al.  Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis , 2002, Nature Medicine.

[34]  Y. Itoyama,et al.  Interferon beta-1b is effective in Japanese RRMS patients , 2005, Neurology.

[35]  R. Rudick,et al.  Defining interferon β response status in multiple sclerosis patients , 2004 .

[36]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[37]  J. Satoh,et al.  Microarray analysis identifies interferon β-regulated genes in multiple sclerosis , 2003, Journal of Neuroimmunology.